1310875-97-8

Upstream product

• 13472-85-0 2-methoxy-5-bromopyridine 
• 1550-35-2 2,4-difluorobenzaldehyde 
• 1310875-96-7 5-(2,4-difluorobenzyl)pyridin-2(1H)-one 
• 1310875-95-6 (2,4-difluorophenyl)(6-methoxypyridin-3-yl)methanol 

Downstream Products

• 1310875-98-9 5-(2,4-difluorobenzyl)-1-(2-fluorobenzyl)-3-iodopyridin-2(1H)-one 
• 1310875-99-0 3-acetyl-5-(2,4-difluorobenzyl)-1-(2-fluorobenzyl)pyridin-2(1H)-one 
• 1310876-00-6 methyl 4-(5-(2,4-difluorobenzyl)-1-(2-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxy-4-oxobut-2-enoate 
• 1310876-01-7 (1S,2S)-4-(5-(2,4-difluorobenzyl)-1-(2-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxy-N-(2-hydroxycyclopentyl)-4-oxobut-2-enamide 
• 1310875-94-5 4-(5-(2,4-difluorobenzyl)-1-(2-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid 
• 1310876-08-4 4-(5-(2,4-difluorobenzyl)-1-(2-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-hydroxy-4-oxo-N-(2-oxopyrrolidin-1-yl)but-2-enamide 

Relevant academic research and scientific papers

Notable difference in anti-HIV activity of integrase inhibitors as a consequence of geometric and enantiomeric configurations

While some examples are known of integrase inhibitors that exhibit potent anti-HIV activity, there are very few cases reported of integrase inhibitors that show significant differences in anti-HIV activity that result from distinctions in cis- and trans-c

PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS

New chiral and achiral oxy- substituted cyclopentyl pyridinone diketocarboxamides and their derivatives and methods for their preparations are disclosed. The compounds include tautomers, regioisomers and geometric isomers. These complex carboxamides are d